These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 20818789)

  • 21. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly.
    Fagan AM; Head D; Shah AR; Marcus D; Mintun M; Morris JC; Holtzman DM
    Ann Neurol; 2009 Feb; 65(2):176-83. PubMed ID: 19260027
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
    Toledo JB; Zetterberg H; van Harten AC; Glodzik L; Martinez-Lage P; Bocchio-Chiavetto L; Rami L; Hansson O; Sperling R; Engelborghs S; Osorio RS; Vanderstichele H; Vandijck M; Hampel H; Teipl S; Moghekar A; Albert M; Hu WT; Monge Argilés JA; Gorostidi A; Teunissen CE; De Deyn PP; Hyman BT; Molinuevo JL; Frisoni GB; Linazasoro G; de Leon MJ; van der Flier WM; Scheltens P; Blennow K; Shaw LM; Trojanowski JQ;
    Brain; 2015 Sep; 138(Pt 9):2701-15. PubMed ID: 26220940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding.
    Tolboom N; van der Flier WM; Yaqub M; Boellaard R; Verwey NA; Blankenstein MA; Windhorst AD; Scheltens P; Lammertsma AA; van Berckel BN
    J Nucl Med; 2009 Sep; 50(9):1464-70. PubMed ID: 19690025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
    Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
    J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alzheimer disease biomarkers are associated with body mass index.
    Vidoni ED; Townley RA; Honea RA; Burns JM;
    Neurology; 2011 Nov; 77(21):1913-20. PubMed ID: 22105948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease.
    Leuzy A; Carter SF; Chiotis K; Almkvist O; Wall A; Nordberg A
    J Alzheimers Dis; 2015; 45(4):1077-88. PubMed ID: 25649653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations of Alcohol Consumption with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
    Wang ZT; Li KY; Tan CC; Xu W; Shen XN; Cao XP; Wang P; Bi YL; Dong Q; Tan L; Yu JT
    J Alzheimers Dis; 2021; 82(3):1045-1054. PubMed ID: 34151793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging.
    Gordon BA; Friedrichsen K; Brier M; Blazey T; Su Y; Christensen J; Aldea P; McConathy J; Holtzman DM; Cairns NJ; Morris JC; Fagan AM; Ances BM; Benzinger TL
    Brain; 2016 Aug; 139(Pt 8):2249-60. PubMed ID: 27286736
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toward a multifactorial model of Alzheimer disease.
    Storandt M; Head D; Fagan AM; Holtzman DM; Morris JC
    Neurobiol Aging; 2012 Oct; 33(10):2262-71. PubMed ID: 22261556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects.
    Apostolova LG; Hwang KS; Andrawis JP; Green AE; Babakchanian S; Morra JH; Cummings JL; Toga AW; Trojanowski JQ; Shaw LM; Jack CR; Petersen RC; Aisen PS; Jagust WJ; Koeppe RA; Mathis CA; Weiner MW; Thompson PM;
    Neurobiol Aging; 2010 Aug; 31(8):1284-303. PubMed ID: 20538372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic Risk as a Marker of Amyloid-β and Tau Burden in Cerebrospinal Fluid.
    Voyle N; Patel H; Folarin A; Newhouse S; Johnston C; Visser PJ; Dobson RJ; Kiddle SJ;
    J Alzheimers Dis; 2017; 55(4):1417-1427. PubMed ID: 27834776
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Onset of Preclinical Alzheimer Disease in Monozygotic Twins.
    Konijnenberg E; Tomassen J; den Braber A; Ten Kate M; Yaqub M; Mulder SD; Nivard MG; Vanderstichele H; Lammertsma AA; Teunissen CE; van Berckel BNM; Boomsma DI; Scheltens P; Tijms BM; Visser PJ
    Ann Neurol; 2021 May; 89(5):987-1000. PubMed ID: 33583080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease.
    Brown BM; Sohrabi HR; Taddei K; Gardener SL; Rainey-Smith SR; Peiffer JJ; Xiong C; Fagan AM; Benzinger T; Buckles V; Erickson KI; Clarnette R; Shah T; Masters CL; Weiner M; Cairns N; Rossor M; Graff-Radford NR; Salloway S; Vöglein J; Laske C; Noble J; Schofield PR; Bateman RJ; Morris JC; Martins RN;
    Alzheimers Dement; 2017 Nov; 13(11):1197-1206. PubMed ID: 28501451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.
    Vlassenko AG; McCue L; Jasielec MS; Su Y; Gordon BA; Xiong C; Holtzman DM; Benzinger TL; Morris JC; Fagan AM
    Ann Neurol; 2016 Sep; 80(3):379-87. PubMed ID: 27398953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings.
    Petrie EC; Cross DJ; Galasko D; Schellenberg GD; Raskind MA; Peskind ER; Minoshima S
    Arch Neurol; 2009 May; 66(5):632-7. PubMed ID: 19433663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease.
    Fagan AM; Mintun MA; Shah AR; Aldea P; Roe CM; Mach RH; Marcus D; Morris JC; Holtzman DM
    EMBO Mol Med; 2009 Nov; 1(8-9):371-80. PubMed ID: 20049742
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
    Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
    JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Social Networks and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study.
    Ma YH; Wang YY; Tan L; Xu W; Shen XN; Wang HF; Hou XH; Cao XP; Bi YL; Dong Q; Yang JL; Yu JT
    J Alzheimers Dis; 2021; 81(1):263-272. PubMed ID: 33749650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in Aβ biomarkers and associations with APOE genotype in 2 longitudinal cohorts.
    Resnick SM; Bilgel M; Moghekar A; An Y; Cai Q; Wang MC; Thambisetty M; Prince JL; Zhou Y; Soldan A; Wong DF; O'Brien RJ; Ferrucci L; Albert MS
    Neurobiol Aging; 2015 Aug; 36(8):2333-9. PubMed ID: 26004017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.